MicroRNA regulation of cell viability and drug sensitivity in lung cancer

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Introduction: microRNAs (miRNAs) are 19 23 nucleotide long RNAs found in multiple organisms that regulate gene expression and have been shown to play important roles in tumorigenesis. In the context of lung cancer, numerous studies have shown that tumor suppressor genes and oncogenes that play crucial roles in lung tumor development and progression are targets of miRNA regulation. Manipulation of miRNA levels that modulate lung cancer cell survival and drug sensitivity can therefore provide novel therapeutic targets and agents. Areas covered: Here, the authors review the published in vitro, in vivo and preclinical studies on the functional role of miRNAs in modulating lung cancer cell viability and drug response, and discuss the limitations and promise of translating current findings into miRNA-based therapeutic and diagnostic strategies. Expert opinion: Although many miRNAs have been identified as potent regulators of cell viability and drug sensitivity in lung cancer, most of them have not been characterized for potential clinical application. Further study is warranted to evaluate translation of the current findings to the clinic to improve the diagnosis and treatment of lung cancer. In addition, most studies have focused on non-small cell lung cancer (NSCLC). It is therefore important to raise interest in investigating miRNAs in small cell lung cancer (SCLC) as well as in comparative studies of miRNA expression and function in different histological subtypes of lung cancer.

Original languageEnglish (US)
Pages (from-to)1221-1239
Number of pages19
JournalExpert Opinion on Biological Therapy
Volume12
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

MicroRNAs
Lung Neoplasms
Cell Survival
Cells
Pharmaceutical Preparations
Tumors
Small Cell Lung Carcinoma
Expert Testimony
Tumor Suppressor Genes
Oncogenes
Gene expression
Non-Small Cell Lung Carcinoma
Carcinogenesis
Nucleotides
Genes
RNA
Gene Expression
Lung
Therapeutics
Neoplasms

Keywords

  • Cell viability
  • Drug response
  • Drug sensitivity
  • MicroRNA
  • Non-small cell lung cancer
  • Oncogene
  • Small cell lung cancer
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

MicroRNA regulation of cell viability and drug sensitivity in lung cancer. / Du, Liqin; Pertsemlidis, Alexander.

In: Expert Opinion on Biological Therapy, Vol. 12, No. 9, 09.2012, p. 1221-1239.

Research output: Contribution to journalArticle

@article{568c6589bc0b46b0b6ef988d7f042d7f,
title = "MicroRNA regulation of cell viability and drug sensitivity in lung cancer",
abstract = "Introduction: microRNAs (miRNAs) are 19 23 nucleotide long RNAs found in multiple organisms that regulate gene expression and have been shown to play important roles in tumorigenesis. In the context of lung cancer, numerous studies have shown that tumor suppressor genes and oncogenes that play crucial roles in lung tumor development and progression are targets of miRNA regulation. Manipulation of miRNA levels that modulate lung cancer cell survival and drug sensitivity can therefore provide novel therapeutic targets and agents. Areas covered: Here, the authors review the published in vitro, in vivo and preclinical studies on the functional role of miRNAs in modulating lung cancer cell viability and drug response, and discuss the limitations and promise of translating current findings into miRNA-based therapeutic and diagnostic strategies. Expert opinion: Although many miRNAs have been identified as potent regulators of cell viability and drug sensitivity in lung cancer, most of them have not been characterized for potential clinical application. Further study is warranted to evaluate translation of the current findings to the clinic to improve the diagnosis and treatment of lung cancer. In addition, most studies have focused on non-small cell lung cancer (NSCLC). It is therefore important to raise interest in investigating miRNAs in small cell lung cancer (SCLC) as well as in comparative studies of miRNA expression and function in different histological subtypes of lung cancer.",
keywords = "Cell viability, Drug response, Drug sensitivity, MicroRNA, Non-small cell lung cancer, Oncogene, Small cell lung cancer, Tumor suppressor gene",
author = "Liqin Du and Alexander Pertsemlidis",
year = "2012",
month = "9",
doi = "10.1517/14712598.2012.697149",
language = "English (US)",
volume = "12",
pages = "1221--1239",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - MicroRNA regulation of cell viability and drug sensitivity in lung cancer

AU - Du, Liqin

AU - Pertsemlidis, Alexander

PY - 2012/9

Y1 - 2012/9

N2 - Introduction: microRNAs (miRNAs) are 19 23 nucleotide long RNAs found in multiple organisms that regulate gene expression and have been shown to play important roles in tumorigenesis. In the context of lung cancer, numerous studies have shown that tumor suppressor genes and oncogenes that play crucial roles in lung tumor development and progression are targets of miRNA regulation. Manipulation of miRNA levels that modulate lung cancer cell survival and drug sensitivity can therefore provide novel therapeutic targets and agents. Areas covered: Here, the authors review the published in vitro, in vivo and preclinical studies on the functional role of miRNAs in modulating lung cancer cell viability and drug response, and discuss the limitations and promise of translating current findings into miRNA-based therapeutic and diagnostic strategies. Expert opinion: Although many miRNAs have been identified as potent regulators of cell viability and drug sensitivity in lung cancer, most of them have not been characterized for potential clinical application. Further study is warranted to evaluate translation of the current findings to the clinic to improve the diagnosis and treatment of lung cancer. In addition, most studies have focused on non-small cell lung cancer (NSCLC). It is therefore important to raise interest in investigating miRNAs in small cell lung cancer (SCLC) as well as in comparative studies of miRNA expression and function in different histological subtypes of lung cancer.

AB - Introduction: microRNAs (miRNAs) are 19 23 nucleotide long RNAs found in multiple organisms that regulate gene expression and have been shown to play important roles in tumorigenesis. In the context of lung cancer, numerous studies have shown that tumor suppressor genes and oncogenes that play crucial roles in lung tumor development and progression are targets of miRNA regulation. Manipulation of miRNA levels that modulate lung cancer cell survival and drug sensitivity can therefore provide novel therapeutic targets and agents. Areas covered: Here, the authors review the published in vitro, in vivo and preclinical studies on the functional role of miRNAs in modulating lung cancer cell viability and drug response, and discuss the limitations and promise of translating current findings into miRNA-based therapeutic and diagnostic strategies. Expert opinion: Although many miRNAs have been identified as potent regulators of cell viability and drug sensitivity in lung cancer, most of them have not been characterized for potential clinical application. Further study is warranted to evaluate translation of the current findings to the clinic to improve the diagnosis and treatment of lung cancer. In addition, most studies have focused on non-small cell lung cancer (NSCLC). It is therefore important to raise interest in investigating miRNAs in small cell lung cancer (SCLC) as well as in comparative studies of miRNA expression and function in different histological subtypes of lung cancer.

KW - Cell viability

KW - Drug response

KW - Drug sensitivity

KW - MicroRNA

KW - Non-small cell lung cancer

KW - Oncogene

KW - Small cell lung cancer

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=84865327159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865327159&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.697149

DO - 10.1517/14712598.2012.697149

M3 - Article

C2 - 22731874

AN - SCOPUS:84865327159

VL - 12

SP - 1221

EP - 1239

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -